REP 9AC (REP 2055)

REP 9AC · Replicor Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for REP 9AC (REP 2055), covering 2016-01-05 to 2016-01-05. Get the full timeline:

Most recent: Clinical Trial Update: Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients [Phase 1, Phase 2]